SLU-PP-332 vs Survodutide
A side-by-side research comparison of SLU-PP-332 and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | SLU-PP-332 | Survodutide |
|---|---|---|
| Full name | SLU-PP-332 (ERR Agonist) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | ~426 Da (small molecule, not a peptide) | 4,500 Da (approximate) |
| Half-life | Not well characterized in humans | 5-7 days |
| Bioavailability | Studied via injection in animals; oral activity under investigation | High (SubQ) |
| Typical dose | No established human dose | 0.6-6.0 mg |
| Frequency | Unknown | Once weekly |
| Route | Injection (preclinical) | Subcutaneous |
SLU-PP-332 reported benefits
- Increases mitochondrial fat-burning (preclinical)
- Improved endurance in animals
- Reduced fat gain without appetite change (animals)
- Acts as an "exercise mimetic"
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.